1. Significant increase in patients receiving extended-release buprenorphine.
2. Uptake of non-extended-release buprenorphine decreased.
3. Efforts to expand the use of buprenorphine and other MOUD options are crucial.
4. Only 25% of individuals with opioid use disorder in the U.S. receive MOUD.
5. Further investigation is warranted into the reductions in non-extended-release buprenorphine uptake, particularly among younger individuals.

Source: JAMA Network Open